RISK FACTORS ASSOCIATED WITH PERIPROSTHETIC OSTEOLYSIS IN HIP REVISION PATIENTS

髋关节翻修患者假体周围骨质溶解相关的危险因素

• 批准号: 7378429
• 负责人: LISA Ann MANDL
• 金额: $ 0.65万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378429
• 关键词: RISK; FACTORS; ASSOCIATED; PERIPROSTHETIC; OSTEOLYSIS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Aims of Study: 1) To evaluate the presence of the systemic inflammatory marker hsCRP in osteoarthritis (OA) patients who have had a total hip arthroplasty (THA) compared to matched total hip arthroplasty OA-THA control patients who do not have periprosthetic osteolysis. 2) To evaluate the presence of elevated serum inflammatory markers (hsCRP, IL-1, IL-6, TNF-alpha) and pro-osteoclast signaling proteins (increased RANKL/OPG ratios) with the presence of osteolysis in OA-THA patients. compared to OA-THA, patients, compared to OA-THA controls who do not have osteolysis. 3) OA-THA patients with osteolysis have an absent of decreased history of bisphosphonate medication use than matched non-osteolytic OA-THA controls. 4) OA-THA patients with osteolysis have a history of an increased frequency and duration of high-impact activities such as running, jogging or walking, when compared to matched non-osteolytic OA-THA controls. Hypothesis: 1) Osteoarthritis (OA) patients who require THA revision due to periprosthetic osteolysis have evidence of systemic inflammation, evidence by elevated serum hsCRP levels, which is not present in matched OA-THA controls without osteolysis, or in OA THA patients undergoing hip revision surgery for reasons other than osteolysis. 2) Inflammatory mediators (hsCPR, IL-1, IL-6, TNF-alpha) and pro-osteoclast signaling proteins (increased RANKL: OPG ratios) are elevated in the sera of OA-THA patients with osteolysis, and are not elevated in OA-THA patients without osteolysis, or in OA-THA patients who require hip revision surgery for reasons other than osteolysis. 3) OA-THA patients with osteolysis have an absent or decreased history of bisphosphonate medication use than matched non-osteolytic OA-THA controls. 4) OA-THA patients with osteolysis have a history of an increased frequency and duration of high-impact activities such as running, jogging or walking, when compared to matched non-osteolytic OA-THA controls

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。研究目的：1) 评估接受全髋关节置换术 (THA) 的骨关节炎 (OA) 患者与没有假体周围骨质溶解的匹配全髋关节置换术 OA-THA 对照患者中全身炎症标志物 hsCRP 的存在情况。 2) 评估 OA-THA 患者是否存在骨溶解，同时血清炎症标志物（hsCRP、IL-1、IL-6、TNF-α）和促破骨细胞信号蛋白（RANKL/OPG 比率升高）升高。与 OA-THA 患者相比，与没有骨溶解的 OA-THA 对照相比。 3) 与匹配的非溶骨性 OA-THA 对照相比，骨溶解的 OA-THA 患者双膦酸盐药物使用史没有减少。 4) 与匹配的非溶骨性 OA-THA 对照相比，患有骨质溶解的 OA-THA 患者有跑步、慢跑或步行等高强度活动的频率和持续时间增加的历史。 假设：1) 因假体周围骨质溶解而需要进行 THA 翻修的骨关节炎 (OA) 患者有全身炎症的证据，血清 hsCRP 水平升高是证据，而在没有骨质溶解的匹配 OA-THA 对照或接受髋关节置换的 OA THA 患者中不存在这种情况。因骨质溶解以外的原因进行翻修手术。 2) 骨溶解的 OA-THA 患者血清中炎症介质（hsCPR、IL-1、IL-6、TNF-α）和促破骨细胞信号蛋白（RANKL: OPG 比值升高）升高，而骨溶解患者血清中炎症介质不升高。无骨溶解的 OA-THA 患者，或因骨溶解以外的原因需要进行髋关节翻修手术的 OA-THA 患者。 3) 与匹配的非溶骨性 OA-THA 对照相比，骨溶解的 OA-THA 患者没有或减少了双膦酸盐药物的使用史。 4) 与匹配的非溶骨性 OA-THA 对照相比，患有骨质溶解的 OA-THA 患者有跑步、慢跑或步行等高强度活动的频率和持续时间增加的历史